STAT Plus: After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows
Alarmed that colleagues were bribing Chinese doctors and giving kickbacks to hospital workers to boost drug sales, an employee at the British pharmaceutical giant GlaxoSmithKline began documenting the alleged crimes in the fall of 2010 and sending detailed notes to the U.S. Securities and Exchange Commission and the U.S. Department of Justice.
Using an anonymous email address, the GSK employee sent similar packages to regulators in China.
